Completed PHASE2 INTERVENTIONAL NCT00003339

Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma

A Randomized Phase II Trial of a Vaccine Combining Tyrosinase/gp100 Peptides Emulsified With Montanide ISA 51 With and Without Interleukin-12 for Patients With Resected Stages III and IV Melanoma

Sponsor: National Cancer Institute (NCI)

Conditions Intraocular Melanoma Melanoma (Skin)

Interventions gp100 antigen incomplete Freund's adjuvant recombinant interleukin-12 tyrosinase peptide

Updated 6 times since 2017 Last updated: May 20, 2014 Started: Nov 30, 1998 Primary completion: Nov 30, 1999 Completion: Sep 30, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Intraocular Melanoma and Melanoma (Skin) and is currently completed. National Cancer Institute (NCI) leads this study, which shows 6 recorded versions since 1998 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Nov 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
University of Southern California

Data source: University of Southern California

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Duarte, United States
• Los Angeles, United States